Natera Begins SIGNAL-ER 101 Trial for MRD-Guided Breast Cancer Therapy
AUSTIN, Texas — May 27, 2026 Natera, Inc. announced the enrollment of the first patients in the SIGNAL-ER 101...
molecular residual disease
Advertisement
Natera Advances Precision Oncology With New Austin Sequencing Hub
Austin, Texas, USA – May 21, 2026 Natera, Inc., a global leader in cell-free DNA testing and precision medicine,...
Ultrasensitive ctDNA Shows Promise in Immunotherapy Monitoring
FREMONT, Calif., Feb. 2, 2026 — Personalis announced the publication of new peer-reviewed clinical evidence demonstrating the value of...
Natera Validates Tissue-Free MRD Test in Colorectal Cancer
Austin, Texas, January 21, 2026 — Natera, a global leader in cell-free DNA and precision medicine, announced the peer-reviewed...
Advertisement
